On April 5, 2011, Senators Debbie Stabenow (R-Mich.) and Pat Roberts (R-Kan.), introduced legislation (S. 733) to promote accurate reimbursement for cancer care drugs. The bill is the companion to the House bill (H.R. 905) introduced in March of this year by Representatives Ed Whitfield (R-Ky.) and Gene Green (D-Texas).

This bipartisan effort enjoys wide support across the health care spectrum, including patient groups, community oncologists, specialty distribution organizations, and pharmaceutical manufacturers. Supporters of this bill include the following organizations: the National Patient Advocacy Foundation, ACCC, Amerisource Bergen, ASCO, COA, Curascript Specialty Distribution, HDMA, Health Coalition, Inc., Patient Services Incorporated, SBDA, SGO, UPMC Cancer Centers, Amgen, Johnson and Johnson, and US Oncology / McKesson.

This 2% prompt pay discount reduction puts pressure on community based cancer care practices, especially when combined with other reductions in cancer care drug reimbursement, including bad debt loss (~5%) and lagging payment updates (~1%).

Click here to contact your Representatives to ask them to co-sponsor this important legislation.

Click here to read a US Oncology one-page legislative review of this legislation. 

US Oncology | 10101 Woodloch Forest | The Woodlands, TX 77380


LegisLink Today

Health Policy Report - December 10, 2014

      The US Oncology Network Get Adobe Reader Terms of Use Contact Us